68779-52-2

Basic information

• Product Name: 2,3,5-TRI-O-BENZYL-1-O-(4-NITROBENZOYL)-D-ARABINOFURANOSE
• Synonyms: 3,4,6-Tri-O-benzyl-α-D-galactopyranose 1,2-(Methyl Orthoacetate);1,2-O-(1-Methoxyethylidene)-3,4,6-tris-O-(phenylMethyl)-α-D-galactopyranose;α-D-Galactopyranose, 1,2-O-(1-Methoxyethylidene)-3,4,6-tris-O-(phenylMethyl)-
• CAS NO: 68779-52-2
• Molecular Formula: C₃₀H₃₄O₇
• Molecular Weight: 0
• Product Categories: 13C & 2H Sugars;Carbohydrates & Derivatives
• Mol File: 68779-52-2.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 601.1°C at 760 mmHg
• Flash Point: 232.1°C
• Appearance: /
• Density: 1.22g/cm³
• Vapor Pressure: 9.07E-14mmHg at 25°C
• Refractive Index: 1.592
• Solubility: Chloroform, Ethyl Acetate, Methanol
• CAS DataBase Reference: 2,3,5-TRI-O-BENZYL-1-O-(4-NITROBENZOYL)-D-ARABINOFURANOSE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3,5-TRI-O-BENZYL-1-O-(4-NITROBENZOYL)-D-ARABINOFURANOSE(68779-52-2)
• EPA Substance Registry System: 2,3,5-TRI-O-BENZYL-1-O-(4-NITROBENZOYL)-D-ARABINOFURANOSE(68779-52-2)

Safety Data

• Hazardous Substances Data: 68779-52-2(Hazardous Substances Data)

Usage

Chemical Properties

Yellowish-Orange Oil

Uses

3,4,6-Tri-O-benzyl-α-D-galactopyranose 1,2-(Methyl Orthoacetate) (cas# 68779-52-2) is a compound useful in organic synthesis.

InChI:InChI=1/C30H34O7/c1-30(31-2)36-28-27(34-20-24-16-10-5-11-17-24)26(33-19-23-14-8-4-9-15-23)25(35-29(28)37-30)21-32-18-22-12-6-3-7-13-22/h3-17,25-29H,18-21H2,1-2H3

Upstream product

• 50801-29-1 3,4,6-tri-O-acetyl-1,2-O-(1-methoxyethylidene)-α-D-galactopyranose 
• 25878-60-8 D-galactose pentaacetate 
• 100-39-0 benzyl bromide 
• 3068-32-4 1-bromo-1-deoxy-2,3,4,6-tetra-O-acetyl-a-D-galactopyranoside 
• 4163-60-4 β-D-galactose peracetate 
• 3068-32-4 1-bromo-2,3,4,6-tetra-O-acetyl-D-galactopyranose 
• 138196-19-7 (3aR,5R,6R,7S,7aR)-5-Hydroxymethyl-2-methoxy-2-methyl-tetrahydro-[1,3]dioxolo[4,5-b]pyran-6,7-diol 
• 100-44-7 benzyl chloride 
• 572-09-8 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide 
• 3254-16-8 3,4,6-tri-O-acetyl-[1,2-O-(1-methoxyethylidene)]-α-D-glucopyranose 
• 83-87-4 D-glucose pentaacetate 
• 572-09-8 2,3,4,6-tetra-O-acetyl-D-glucopyranosyl bromide 
• 29073-91-4 (3aR,5R,6S,7S,7aR)-5-Hydroxymethyl-2-methoxy-2-methyl-tetrahydro-[1,3]dioxolo[4,5-b]pyran-6,7-diol 
• 3947-62-4 2,3,4,5-tetra-O-acetyl-D-glucopyranose 

Downstream Products

• 69435-20-7 C₅₀H₆₂O₉ 
• 79218-68-1 2-O-acetyl-3,4,6-tri-O-benzyl-D-glucopyranose 
• 77790-46-6 1,2-di-O-acetyl-3,4,6-tri-O-benzyl-β-D-galactopyranose 
• 81969-44-0 1,2-di-O-acetyl-3,4,6-tri-O-benzyl-D-galactopyranose 
• 20672-66-6 3,4,5-tri-O-benzyl-D-galactopyranose 
• 77790-47-7 2-O-acetyl-3,4,6-tri-O-benzyl-α-D-galactopyranosyl bromide 
• 55628-56-3 1,2-di-O-acetyl-3,4,6-tri-O-benzyl-β-D-glucopyranoside 
• 138925-14-1 phenyl 2-O-acetyl-3,4,6-tri-O-benzyl-β-D-glucopyranoside 
• 152871-96-0 phenyl 1-deoxy-2-O-acetyl-3,4,6-tri-O-benzyl-1-thio-β-D-glucopyranoside 
• 135583-76-5 phenyl 2-O-acetyl-3,4,6-tri-O-benzyl-1-seleno-β-D-glucopyranoside 
• 183875-29-8 phenyl 3,4,6-tri-O-benzyl-1-thio-β-D-galactopyranoside 
• 259871-00-6 phenyl 3,4,6-tri-O-benzyl-2-O-(3-carboxypropionyl)-1-thio-β-D-galactopyranoside 
• 259871-07-3 benzyl O-(3',4',6'-tri-O-benzyl-α-D-galactopyranosyl)-(1->4)-2-O-benzoyl-6-O-benzyl-α-D-glucopyranoside-2',3'-succinate 
• 259871-01-7 phenyl 3,4,6-tri-O-benzyl-2-O-(2-O-benzoyl-1-O-benzyl-4,6-O-benzylidene-α-D-glucopyranos-3-yloxycarbonylpropanoyl)-1-thio-β-D-galactopyranoside 

Relevant articles and documents

Exploring the Biochemical Foundations of a Successful GLUT1-Targeting Strategy to BNCT: Chemical Synthesis and in Vitro Evaluation of the Entire Positional Isomer Library of ortho-Carboranylmethyl-Bearing Glucoconjugates

Boron neutron capture therapy (BNCT) is a noninvasive binary therapeutic modality applicable to the treatment of cancers. While BNCT offers a tumor-targeting selectivity that is difficult to match by other means, the last obstacles preventing the full har

Exploring glycosylation reactions under continuous-flow conditions

The industrial development of carbohydrate-based drugs is greatly thwarted by the typical challenges inherent in oligosaccharide synthesis. The practical advantages of continuous-flow synthesis in microreactors (high reproducibility, easy scalability, and fast reaction optimization) may offer an effective support to make carbohydrates more attractive targets for drug-discovery processes. Here we report a systematic exploration of the glycosylation reaction carried out under microfluidic conditions. Trichloroacetimidates and thioglycosides have been investigated as glycosyl donors, using both primary and secondary acceptors. Each microfluidic glycosylation has been compared with the corresponding batch reaction, in order to highlight advantages and drawbacks of microreactors technology. As a significant example of multistep continuous-flow synthesis, we also describe the preparation of a trisaccharide by means of two consecutive glycosylations performed in interconnected microreactors.

Synthetic oligosaccharides as tools to demonstrate cross-reactivity between polysaccharide antigens

Escherichia coli O148 is a nonencapsulated enterotoxigenic (ETEC) Gram negative bacterium that can cause diarrhea, hemorrhagic colitis, and hemolytic uremic syndrome in humans. The surface-exposed O-specific polysaccharide (O-SP) of the lipopolysaccharide